MedDataX Logo

Model-informed Individualized Treatment of Anti-infective Drugs

NCT ID: NCT06711562

Last Updated: 2024-12-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-10-12

Study Completion Date

2026-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study aims to optimize individualized treatment of anti-infective drugs in osteoarticular infections by analyzing drug exposure in patients blood and/or tissues using population pharmacokinetics.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoarticular Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Anti-Infective Drugs

Anti-infective drugs are administered using the traditional clinical dosing regimen, with no interventions.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with suspected/confirmed osteoarticular infections who are undergoing anti-infective drug therapy.

Exclusion Criteria

* Pregnant/lactating women.
* There are other factors that the researchers think are not suitable for inclusion.
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shandong University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Wei Zhao

Head of department of clinical pharmacy and pharmacology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Wei Zhao, Ph.D

Role: PRINCIPAL_INVESTIGATOR

Shandong University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Shandong Public Health Clinical Center

Jinan, , China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Wei Zhao, Ph.D

Role: CONTACT

[email protected]
86053188383308

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Qiang Zhang

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SDU-2024-BJ-005

Identifier Type: -

Identifier Source: org_study_id